BioCentury | Dec 2, 2010
Distillery Therapeutics

Indication: Hematology

...effectiveness of other HSC-based therapies. KN38-7271 (formerly BAY 38-7271), a CNR1 and CNR2 agonist from KeyNeurotek AG...
BioCentury | Dec 21, 2009
Clinical News

KN38-7271: Phase IIa data

...in the EU to treat moderate to severe TBI. KeyNeurotek licensed the compound from Bayer. KeyNeurotek AG...
BioCentury | Aug 31, 2009
Emerging Company Profile

TauTaTis: Tau now

...German startup Nadag AG, which was subsequently acquired by Sirenade Pharmaceuticals AG (now part of KeyNeurotek AG...
...through SBIR money and NIH grants. Companies and Institutions Mentioned Bayer AG (Xetra:BAY), Leverkusen, Germany KeyNeurotek AG...
BioCentury | Dec 22, 2008
Clinical News

KN38-7271: Completed Phase IIa enrollment

...in the EU to treat moderate to severe TBI. KeyNeurotek licensed the compound from Bayer. KeyNeurotek AG...
BioCentury | Sep 29, 2008
Clinical News

KN38-7271 regulatory update

...EMEA granted Orphan Drug designation for KeyNeurotek's KN38-7271 to treat moderate and severe closed traumatic brain...
...expected later this half. The company licensed the compound from Bayer AG (Xetra:BAY, Leverkusen, Germany). KeyNeurotek AG...
BioCentury | May 12, 2008
Clinical News

KN38-7271: Phase I data

...half-life was 9-15 hours for the low dose and 14-22 hours for the high dose. KeyNeurotek AG...
BioCentury | Nov 12, 2007
Clinical News

KN38-7271: Phase I started

...double-blind, dose-escalation Phase I trial in healthy volunteers. The company licensed the compound from BAY. KeyNeurotek AG...
BioCentury | Mar 12, 2007
Product Development

Key to bladder relief

...effects are seen at even higher doses than those needed for analgesia. Furthermore, said Striggow, KeyNeurotek...
...difficult for thrill seekers to extract active ingredient to make it available for such use. KeyNeurotek...
...studies in parallel, he said. The company then hopes to partner or out-license the product. KeyNeurotek's...
BioCentury | Mar 5, 2007
Company News

Gruenenthal GmbH, KeyNeurotek deal

...or overactive bladder in 2H07. Financial terms were not disclosed. Gruenenthal GmbH , Aachen, Germany KeyNeurotek AG...
BioCentury | Feb 19, 2007
Company News

KeyNeurotek, Max Planck Society deal

...central nervous system, such as stroke or Parkinson’s disease (PD). Financial terms were not disclosed. KeyNeurotek AG...
Items per page:
1 - 10 of 27
BioCentury | Dec 2, 2010
Distillery Therapeutics

Indication: Hematology

...effectiveness of other HSC-based therapies. KN38-7271 (formerly BAY 38-7271), a CNR1 and CNR2 agonist from KeyNeurotek AG...
BioCentury | Dec 21, 2009
Clinical News

KN38-7271: Phase IIa data

...in the EU to treat moderate to severe TBI. KeyNeurotek licensed the compound from Bayer. KeyNeurotek AG...
BioCentury | Aug 31, 2009
Emerging Company Profile

TauTaTis: Tau now

...German startup Nadag AG, which was subsequently acquired by Sirenade Pharmaceuticals AG (now part of KeyNeurotek AG...
...through SBIR money and NIH grants. Companies and Institutions Mentioned Bayer AG (Xetra:BAY), Leverkusen, Germany KeyNeurotek AG...
BioCentury | Dec 22, 2008
Clinical News

KN38-7271: Completed Phase IIa enrollment

...in the EU to treat moderate to severe TBI. KeyNeurotek licensed the compound from Bayer. KeyNeurotek AG...
BioCentury | Sep 29, 2008
Clinical News

KN38-7271 regulatory update

...EMEA granted Orphan Drug designation for KeyNeurotek's KN38-7271 to treat moderate and severe closed traumatic brain...
...expected later this half. The company licensed the compound from Bayer AG (Xetra:BAY, Leverkusen, Germany). KeyNeurotek AG...
BioCentury | May 12, 2008
Clinical News

KN38-7271: Phase I data

...half-life was 9-15 hours for the low dose and 14-22 hours for the high dose. KeyNeurotek AG...
BioCentury | Nov 12, 2007
Clinical News

KN38-7271: Phase I started

...double-blind, dose-escalation Phase I trial in healthy volunteers. The company licensed the compound from BAY. KeyNeurotek AG...
BioCentury | Mar 12, 2007
Product Development

Key to bladder relief

...effects are seen at even higher doses than those needed for analgesia. Furthermore, said Striggow, KeyNeurotek...
...difficult for thrill seekers to extract active ingredient to make it available for such use. KeyNeurotek...
...studies in parallel, he said. The company then hopes to partner or out-license the product. KeyNeurotek's...
BioCentury | Mar 5, 2007
Company News

Gruenenthal GmbH, KeyNeurotek deal

...or overactive bladder in 2H07. Financial terms were not disclosed. Gruenenthal GmbH , Aachen, Germany KeyNeurotek AG...
BioCentury | Feb 19, 2007
Company News

KeyNeurotek, Max Planck Society deal

...central nervous system, such as stroke or Parkinson’s disease (PD). Financial terms were not disclosed. KeyNeurotek AG...
Items per page:
1 - 10 of 27